
## Validation data for Anti-hIL-4R-hIgG4 (S228P)

https://www.invivogen.com/anti-human-il-4r-dupilumab-biosimilar-antibody

## For research use only

Version 25C26-AK

Anti-hIL4R-hIgG4 (S228P) is the biosimilar of the therapeutic monoclonal antibody (mAb) dupilumab. Dupilumab specifically binds to the human interleukin 4 receptor (hIL-4R). It blocks the binding of IL-4 and IL-13 and thus, inhibits the downstream STAT6-dependent pro-inflammatory response. The inhibitory activity of the biosimilar mAb Anti-hIL-4R-hIgG4 (S228P) has been validated using InvivoGen's HEK-Blue<sup>™</sup> IL-4/IL-13 cellular assay (Figure 1).



## Dose-dependent neutralization of IL-4 and IL-13 signaling

**Figure 1.** Anti-hlL-4R-hlgG4 (S228P) is a potent neutralization antibody.  $HEK-Blue^{IM}$  IL-4/IL-13 cells were incubated with increasing concentrations of Anti-hlL-4R-hlgG4 (S228P) (0.1 ng - 10 µg) for 1 h prior to the addition of either recombinant human IL-4 (1 ng/ml) or recombinant human IL-13 (1 ng/ml). After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue<sup>IM</sup> Solution. Data are shown in percentage of activity (mean ± SEM).

